Funding Isn’t Everything: Bringing Pharma to the Table for the Pasteur Act
October 8th 2024The pharmaceutical industry faces challenges when investing in new antibiotics, which emphasizes the need for regulatory reforms, incentives, and collaborative efforts between government, healthcare organizations, and private companies. The prospective bill, the Pasteur Act, is one potential strategy to help in these areas, and incentivize pharmaceutical companies to develop these essential therapies.
Top 5 Infectious Disease News Stories Week of September 27-October 4
October 5th 2024Healthcare workers receiving additional COVID-19 vaccine doses had fewer ongoing symptoms, a new test differentiates bacterial from viral infections, CDC reports 10 deaths linked to ongoing listeria outbreak, and more this week from Contagion.
GigaGen's New Contract with BARDA for Polyclonal Antibody Development
October 4th 2024Carter Keller discusses the company's recent $135.2 million contract with BARDA to develop recombinant polyclonal antibody therapies targeting botulinum neurotoxins and an unspecified biothreat, highlighting their innovative approach to address emerging health threats.
Evaluating Safety and Efficacy of Vaxart's Oral Vaccine's Impact on COVID-19 Variants
October 4th 2024Part 2 with James F Cummings, MD, as he discusses the need for a stronger response to emerging variants, the importance of protecting high-risk populations, and the potential to reduce vaccine hesitancy through easier administration.